Phase 2 KEYLYNK-007 trial findings suggest a new avenue through the combination of olaparib and pembrolizumab in previously treated solid tumors harboring homologous recombination repair mutations and/or homologous recombination deficiency. #lungcancer
https://www.oncologynewscentral.com/oncology/tumor-agnostic-trial-finds-parp-inhibitor-and-anti-pd-l1-combo-beneficial-across-cancer-types